Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  XenoPort, Inc.    XNPT

Delayed Quote. Delayed  - 05/05 09:59:59 pm
4.12 USD   -2.14%
05/05 XENOPORT : reports 1Q loss
05/05 XENOPORT : Reports First Quarter Financial Results
04/26 XENOPORT : to Release First Quarter Financial Results on May 5, 2016
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

XenoPort, Inc. : XenoPort Announces New Employment Inducement Award

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/01/2012 | 11:05pm CEST

XenoPort, Inc. (Nasdaq:XNPT) reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employee, Sayuri Ino, was granted restricted stock units representing an aggregate of 500 shares of XenoPort's common stock. The restricted stock units vest in four equal annual installments on anniversaries of the June 1, 2012 grant date. The equity award was approved by the independent compensation committee of XenoPort's board of directors and was granted as an inducement material to the new employee entering into employment with XenoPort in accordance with Nasdaq Market Place Rule 5635(c)(4).

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is XenoPort's first U.S. Food and Drug Administration-approved product. GlaxoSmithKline holds commercialization rights and certain development rights for Horizant in the United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved for the treatment of moderate-to-severe primary restless legs syndrome in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPort's pipeline of product candidates includes potential treatments for patients with postherpetic neuralgia, spasticity and Parkinson's disease.

To learn more about XenoPort, please visit the company Website at www.XenoPort.com.

Horizant is a registered U.S. trademark of GSK.

XENOPORT is a registered trademark of XenoPort, Inc.

Regnite is a registered trademark of Astellas.

XNPT2G

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on XENOPORT, INC.
05/05 XENOPORT : reports 1Q loss
05/05 XENOPORT INC : Results of Operations and Financial Condition, Financial Statemen..
05/05 XENOPORT : Reports First Quarter Financial Results
04/26 XENOPORT : to Release First Quarter Financial Results on May 5, 2016
04/11 XENOPORT : Entry into a Material Definitive Agreement, Creation of a Direct Fina..
04/01 XENOPORT : Change in Directors or Principal Officers (form 8-K)
03/29 DR REDDY LABORATORIES : In pact with xenoport to develop psoriasis drug
03/29 DR REDDY LABORATORIES : Inks pact with xenoport for psoriasis drug
03/28 XENOPORT : Entry into a Material Definitive Agreement (form 8-K)
03/28 XENOPORT : Dr. Reddy's Laboratories and XenoPort Enter into a U.S. Licensing Agr..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials